Term ends Aug 8, 2027 · High confidence
20-year base term ended Feb 3, 2026
Held by Intarcia Therapeutics, Inc.
Filed Feb 3, 2006 as application 11/347,562 · Granted Feb 14, 2012
Base term plus 1502 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2006
2027
Clock starts
Feb 3, 2006
Feb 3, 2006
Term ends
Aug 8, 2027
Aug 8, 2027
Granted
Feb 14, 2012
Feb 14, 2012
base term
patent term adjustment
fee events
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
1,502
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 7,682,356.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
23
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 1502 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 3, 2006, when this application, 11/347,562, was filed | Feb 3, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +1502 days, USPTO patent term adjustment record | Mar 16, 2030 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,682,356) | capped to Aug 8, 2027 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Aug 8, 2027 | High confidence |
This family
| US 8,114,437 | this patent Aug 2027 | Aug 2027 |
| US 8,052,996 | In force no later than Feb 2029 | no later than Feb 2029 |
| US 8,299,025 | Term ended Feb 2026 | Feb 2026 |
| US 8,211,467 | Term ended Feb 2026 | Feb 2026 |
| US 8,940,316 | In force no later than Jan 2029 | no later than Jan 2029 |
| US 8,206,745 | Term ended Feb 2026 | Feb 2026 |
| US 8,158,150 | Term ended Feb 2026 | Feb 2026 |
| US 8,273,365 | Term ended Feb 2026 | Feb 2026 |
8 of 23 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 10, 2006 Reel 17885, frame 733 | Rohloff, Catherine M.; Chen, Guohau; Luk, Andrew S.; Ayer, Rupal A.; Houston, Paul R.; Desjardin, Michael A.; Zamora, Pauline; Lam, Stan | Alza Corporation | Assignment of Assignor's Interest |
| Dec 13, 2007 Reel 20252, frame 143 | Alza Corporation | Intarcia Therapeutics, Inc. | Assignment of Assignor's Interest |
| Sep 8, 2010 Reel 24953, frame 525 | Intarcia Therapeutics, Inc. | Oxford Finance Corporation; Silicon Valley Bank | Security Agreement |
| Sep 8, 2010 reel/frame not recorded | Intarcia Therapeutics, Inc. | Oxford Finance Corporation | Security Agreement |
| Sep 8, 2010 reel/frame not recorded | Intarcia Therapeutics, Inc. | Silicon Valley Bank | Security Agreement |
| Sep 23, 2011 Reel 26962, frame 62 | Oxford Finance Corporation; Silicon Valley Bank | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Nov 14, 2012 Reel 29299, frame 678 | Intarcia Therapeutics, Inc. | U.S. Bank National Association, as Collateral Agent | Security Agreement |
| Oct 23, 2015 Reel 36942, frame 544 | U.S. Bank National Association, as Collateral Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Oct 9, 2019 Reel 50673, frame 20 | Intarcia Therapeutics, Inc.; Intarcia Ireland Limited | Midcap Financial Trust, As Agent | Security Interest |
| Oct 23, 2019 Reel 50801, frame 267 | Intarcia Therapeutics, Inc. | Baupost Private Investments Bviv-3, L.L.C., as Collateral Agent | Security Interest |
| Jan 29, 2020 Reel 51739, frame 453 | Baupost Private Investments Bviv-3, L.L.C. as Collateral Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Apr 17, 2020 Reel 52433, frame 1 | Midcap Financial Trust, As Agent | Intarcia Therapeutics, Inc.; Intarcia Ireland Limited | Release of Security Interest |
| Apr 17, 2020 reel/frame not recorded | Midcap Financial Trust, As Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Apr 17, 2020 reel/frame not recorded | Midcap Financial Trust, As Agent | Intarcia Ireland Limited | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Aug 2027
Term ends Aug 8, 2027. No further fees fall due before then
Note
The 1502 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 7,682,356.
Citations
99
later US patents cite this one
That is top 10% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.